Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Colclough, Nicola; Chen, Kan; Johnström, Peter; Strittmatter, Nicole; Yan, Yumei; L. Wrigley, Gail; Schou, Magnus; J. A. Goodwin, Richard; Varnäs, Katarina; J. Adua, Sally; Zhao, Minghui; X. Nguyen, Don; Maglennon, Gareth; Barton, Peter; Atkinson, James; Zhang, Lin; Janefeldt, Annika; Wilson, Joanne; Smith, Aaron; Takano, Akihiro; Arakawa, Ryosuke; Kondrashov, Mikhail; Malmquist, Jonas; Revunov, Evgeny; Vázquez‐Romero, Ana; Mahdi Moein, Mohammad; D. Windhorst, Albert; A. Karp, Natasha; Raymond V. Finlay, M.; A. Ward, Richard; Yates, James; D. Smith, Paul; Farde, Lars; Cheng, Zack; A.E. Cross, Darren

doi:10.1158/1078-0432.ccr-19-1871

Public

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Published in Clinical Cancer Research • Oct 7, 2020

Authors:

Nicola Colclough

Kan Chen

Peter Johnström

Abstract

Abstract Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood–brain barrier (BBB) permeability is considered desirable for increasing clinical efficacy. Experimental Desig...

Subject

Osimertinib

Blood–brain barrier

In vivo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!